Chemistry

The panorama of most cancers cell line metabolism


1.

Vander Heiden, M. G. et al. Understanding the Warburg impact: the metabolic necessities of cell proliferation. Science 324, 1029–1034 (2009).

2.

Pavlova, N. N. & Thompson, C. B. The rising hallmarks of most cancers metabolism. Cell. Metab. 23, 27–47 (2016).

Three.

Cairns, R. A., Harris, I. S. & Mak, T. W. Regulation of most cancers cell metabolism. Nat. Rev. Most cancers 11, 85–95 (2011).

four.

Vander Heiden, M. G. & Deberardinis, R. J. Understanding the intersections between metabolism and most cancers biology. Cell 168, 657–669 (2017).

5.

Tennant, D. A., Durán, R. V. & Gottlieb, E. Concentrating on metabolic transformation for most cancers remedy. Nat. Rev. Most cancers 10, 267–277 (2010).

6.

McDonald, E. R. I. et al. Undertaking DRIVE: a compendium of most cancers dependencies and artificial deadly relationships uncovered by large-Scale, deep RNAi screening. Cell 170, 577–592 (2017).

7.

Barretina, J. et al. The Most cancers Cell Line Encyclopedia permits predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).

eight.

Tsherniak, A. et al. Defining a most cancers dependency map. Cell 170, 564–576 (2017).

9.

Ghandi, M. et al. Subsequent-generation characterization of the Most cancers Cell Line Encyclopedia. Nature https://doi.org/10.1038/s41586-Zero19-1186-Three (2019).

10.

Xu, W. et al. Oncometabolite 2-hydroxyglutarate is a aggressive inhibitor of a ketoglutarate-dependent dioxygenases. Most cancers Cell. 19, 17–30 (2011).

11.

Dang, L. et al. Most cancers-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739–744 (2009).

12.

Shim, E. H. et al. L-2-hydroxyglutarate: An epigenetic modifier and putative oncometabolite in renal most cancers. Most cancers Discov. four, 1290–1298 (2014).

13.

Wakabayashi, N. et al. Safety in opposition to electrophile and oxidant stress by induction of the part 2 response: destiny of cysteines of the Keap1 sensor modified by inducers. Proc. Natl Acad. Sci. USA 101, 2040–2045 (2004).

14.

Ohta, T. et al. Lack of Keap1 perform prompts Nrf2 and supplies benefits for lung most cancers cell development. Most cancers Res. 68, 1303–1309 (2008).

15.

Dey, P. et al. Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic most cancers. Nature 542, 119–123 (2017).

16.

Meyers, R. M. et al. Computational correction of copy quantity impact improves specificity of CRISPR-Cas9 essentiality screens in most cancers cells. Nat. Genet. 49, 1779–1784 (2017).

17.

Indiveri, C., Tonazzi, A., Prezioso, G. & Palmieri, F. Kinetic characterization of the reconstituted carnitine service from rat liver mitochondria. Biochim. Biophys. Acta 1065, 231–238 (1991).

18.

Yang, W. S. et al. Regulation of ferroptotic most cancers cell dying by GPX4. Cell 156, 317–331 (2014).

19.

Yu, C. et al. Excessive-throughput identification of genotype-specific most cancers vulnerabilities in mixtures of barcoded tumor cell strains. Nat. Biotechnol. 34, 419–423 (2016).

20.

Mezrich, J. D. et al. An Interplay between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 185, 3190–3198 (2010).

21.

Uyttenhove, C. et al. Proof for a tumoral immune resistance mechanism primarily based on tryptophan degradation by indoleamine 2,Three-dioxygenase. Nat. Med. 9, 1269–1274 (2003).

22.

Munn, D. H. & Mellor, A. L. Indoleamine 2,Three dioxygenase and metabolic management of immune responses. Developments Immunol. 34, 137–143 (2013).

23.

Brochez, L., Chevolet, I. & Kruse, V. The rationale of indoleamine 2,Three-dioxygenase inhibition for most cancers remedy. Eur. J. Most cancers 76, 167–182 (2017).

24.

Jain, M. et al. Metabolite profiling identifies a key function for glycine in fast most cancers cell proliferation. Science 336, 1040–1044 (2012).

25.

Lengthy, G. V. Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in sufferers (pts) with unresectable or metastatic melanoma: outcomes of the part Three ECHO-301/KEYNOTE-252 examine. J. Clin. Oncol. 36, abstr. 108 (2018).

26.

Narta, U. Okay., Kanwar, S. S. & Azmi, W. Pharmacological and medical analysis of L-asparaginase within the remedy of leukemia. Crit. Rev. Oncol. Hematol. 61, 208–221 (2007).

27.

Hettmer, S. et al. Purposeful genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcoma. eLife four, 1–17 (2015).

28.

Knott, S. R. V. et al. Asparagine bioavailability governs metastasis in a mannequin of breast most cancers. Nature 554, 378–381 (2018).

29.

Townsend, M. Okay. et al. Reproducibility of metabolomic profiles amongst women and men in 2 massive cohort research. Clin. Chem. 59, 1657–1667 (2013).


Supply hyperlink
asubhan

wordpress autoblog

amazon autoblog

affiliate autoblog

wordpress web site

web site improvement

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close